Interestingly, we found that in BRCA, HNSC, KIRC, PAAD, PRAD and UVM, RBM15 expression was significantly associated with more than 30 immune checkpoint markers, such as TNFRSF9, CD86, TIGIT, CD80, etc. (Figure 8). This evidence concerns the gene CD86 and prostate adenocarcinoma.